M&A

News

Digital health financing shows signs of recovery in H1

After languishing in the doldrums for a few quarters, there are signs that the winds of investment are starting to blow again in the US digital health sector, according to market watcher Ro

News

Lilly swoops on Morphic to claim IBD drug candidate

Eli Lilly has bolstered its inflammatory bowel disease (IBD) pipeline with a $3.2 billion bid to acquire Morphic and its mid-stage oral integrin therapy MORF-057.

News

Grifols' executive chairman Thomas Glanzmann (l) and chief executive Nacho Abia (r)

Could Spain’s Grifols be heading for de-listing?

The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almo

News

Radionetics Oncology's chief executive Paul Grayson

Lilly builds in radiopharma with $140m Radionetics deal

Eli Lilly has lined up another deal in the radiopharmaceutical sector, paying $140 million to partner drugs developed by Radionetics Oncology and taking an option on buying the company outr

News

Vanda bats away unwanted Cycle, Future Pak takeover bids

Vanda Pharmaceuticals' board is unimpressed with takeover offers from both Cycle Pharma and Future Pak, saying they both “substantially undervalue” the company.

News